With the rapid decline in average sales price of reference pegfilgrastim products due to biosimilar competition, health care institutions and payers may grapple with coverage of Neulasta Onpro.
Caleb J. Scheckel, DO
Advertisement
Articles by Caleb J. Scheckel, DO
Advertisement
Latest Updated Articles
- Neulasta Onpro: A Coup de Grâce?
March 13th 2023
Advertisement
Advertisement
Trending on AJMC
1
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
2
FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance
3
Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups
4
ATTR-CM Incidence, Prevalence Rose Sharply in the US
5